Vivos Therapeutics (VVOS) Capital Leases (2025 - 2026)

Vivos Therapeutics (VVOS) posted quarterly Capital Leases of $98000.0 for Q1 2026, down 13.27% quarter-over-quarter from $113000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Capital Leases (2025 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has reported Capital Leases for 2 consecutive years, with $98000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Capital Leases changed N/A year-over-year to $98000.0; the TTM figure through Mar 2026 stood at $98000.0 (changed N/A YoY), while the FY2025 annual figure was $113000.0, changed N/A from the prior year.
Capital Leases eased to $98000.0 in Q1 2026 per VVOS's latest filing, from $113000.0 in the prior quarter.
Across five years, Capital Leases topped out at $141000.0 in Q2 2025 and bottomed at $98000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn
10	Vivos Therapeutics	5.18 Mn	3.38 Mn	2.95 Mn

Download Data